Navigation Links
Drug Cures Osteoporosis in Mice
Date:2/8/2010

Experimental agent targets serotonin in the gut, triggering bone formation

MONDAY, Feb. 8 (HealthDay News) -- An experimental drug that inhibits serotonin in the gut cured osteoporosis in lab mice and rats, a new study has found.

Previous research has shown that serotonin in the gut hinders bone formation. Most current drugs for osteoporosis only prevent the breakdown of bone; they don't build bone.

"New therapies that inhibit the production of serotonin in the gut have the potential to become a [new] class of drugs to be added to the therapeutic arsenal against osteoporosis," study author Dr. Gerard Karsenty, chairman of the department of genetics and development at Columbia University College of Physicians and Surgeons, said in a university news release.

In the new study, published in the Feb. 7 issue of Nature Medicine, small daily doses of the new drug were given by mouth for up to six weeks to rodents with postmenopausal osteoporosis. The treatment prevented osteoporosis from developing or fully cured rodents in which osteoporosis was already present.

While the drug inhibited serotonin in the gut, levels of serotonin remained normal in the rodents' brains. This indicates that the drug didn't enter general circulation and wasn't able to cross the blood-brain barrier, thus greatly reducing the risk of side effects.

"With tens of millions of people worldwide affected by this devastating and debilitating bone loss, there is an urgent need for new treatments that not only stop bone loss but also build new bone. Using these findings, we are working hard to develop this type of treatment for human patients," Karsenty said.

More information

The American College of Rheumatology has more about osteoporosis.



-- Robert Preidt



SOURCE: Columbia University, news release, Feb. 7, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Constipations Many Causes and Cures
2. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
3. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
4. Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn
5. UI licensee Optherion secures $37 million in financing
6. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
7. Piedmont Pharmaceuticals Secures $8.5 Million Investment
8. St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chilis Care Center
9. The blood-brain barrier: A misunderstood key to finding life-saving cures to brain disease
10. Study paves way for development of macular degeneration cures
11. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... , ... December 08, 2016 , ... David J. ... global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, ... the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... December 9, 2016 External ... Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators ... Cardioverter Defibrillators The global defibrillators ... CAGR of 5.3% from 2016-2020 and CAGR of ... grow at a CAGR of 5.2% from 2016 ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... the global optical transceiver market to grow at a CAGR of ... the present scenario and the growth prospects of the global optical ... considers the revenue generated from the shipment of optical transceivers worldwide ...
(Date:12/9/2016)... 9, 2016 Mitsubishi Tanabe Pharma Corporation (Head ... Director, CEO: Dr. Masayuki Mitsuka ) has presented ... given edaravone intravenously in 10-14 day cycles for 48 ... the ALS Functional Rating Scale-Revised (ALSFRS-R). The data were ... ALS/MND in Dublin, Ireland . ...
Breaking Medicine Technology: